NESS ZIONA, ISRAEL -- Nano Dimension will form a new subsidiary and will transition its bio-printing activities to the new entity.

The new subsidiary will expedite research and development in this field. As previously reported by Nano Dimension, Nano Dimension's current capital will not be used for the bio-printing activities.

In May Nano Dimension announced a successful proof of concept for 3D printing of bio-ink containing stem cells. The feasibility tests demonstrated the potential to print tissues derived from viable stem cells. The process uses 3D printer inkjet technology developed by Nano Dimension.

Recently several companies have expressed interest in Nano Dimension's bio-printing technology, as a result, the board of directors of the company has approved the transition of this activity to a new entity.

IDTechEx forecasts the market for 3D bio-printing will grow rapidly over the next decade from a market size of $481 million in 2014 to as much as $6 billion in 2024.

Submit to FacebookSubmit to Google PlusSubmit to TwitterSubmit to LinkedInPrint Article